Previously untreated HL: early PET response-adapted treatment yields impressive 5-y PFS
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
Significantly improved 5-y PFS was seen in patients with Hodgkin's lymphoma (HL) who switched to bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPesc) + involved-node radiotherapy (INRT) after positive positron emission tomography (PET) after 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD).
Why this matters
There is no current method for predicting which patients may benefit by sparing INRT.
Study of an early PET response-adapted strategy in 1950 patients with previously untreated stage I and II HL.
Patients were categorized by favorable/unfavorable disease per European Organisation for Research and Treatment of Cancer (EORTC) criteria.
All patients received 2 cycles of ABVD before early PE...